fda drug safety communication semaglutide naion 2025 November 2025 Drug Safety: Recalls for Compounded Semaglutide, Generic Synthroid; Safety updates for Lamictal, Kineret, Miebo eye drops, Zoladex; Microneedling Injuries, more

📍 Retina World Congress coverage As GLP-1 drugs become more widely used, retina specialists are closely watching the emerging ocular safety data. Rishi P. Singh, MD, reviewed the latest evidence on diabetic

24.72

★★★★☆4.8 (126)

The use of semaglutide in patients with diabetes was associated with a significantly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION) compared with those taking drugs for diabetes that belong to

20.76

★★★★★4.9 (98)

You've seen the headlines. Should you be worried about semaglutide medications, like Ozempic, leading to vision loss? Read the full story on Today Show https://ow.ly/zeEX50WBHhz

20.06

★★★★★5.0 (157)

Ozempic Lawsuit for Blindness, Stomach Paralysis and Injury Claims

20.12

★★★★★4.7 (84)

The obesity drug semaglutide (Wegovy) conferred a significantly higher risk of ischemic optic neuropathy (ION) than any other GLP-1 agonist, including semaglutide for diabetes (Ozempic), an analysis of FDA data showed. Added

26.73

★★★★★4.9 (203)

The FDA just closed a 2-year investigation into GLP-1 drugs like Ozempic and Wegovy and the question was a serious one: do these medications raise the risk of suicidal thoughts? The short

28.05

★★★★★5.0 (176)

FDA has approved a new oral form of semaglutide for long-term weight reduction in adults with obesity or overweight. The new oral tablet is also indicated for reducing the risk of major

23.71

★★★★★4.8 (132)